$XCUR Cashflow Statement | Understand Stock

$XCUR

$1.07 -$0.02 (1.83%) Close

$XCUR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization
Amortization of right-of-use asset
Equity-based compensation
Amortization of long-term debt issuance costs and fees
Amortization of investments
Right-of-use asset impairment loss
Change in fair value of contingent consideration
Gain on early lease termination
Gain on settlement of accounts payables
Changes in fair value of investment in convertible notes receivable
Loss on disposal/sale of subsidiary
Loss from sale of property and equipment
Other
Change in fair value of warrant liabilities
Income tax benefit
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Other noncurrent assets
Accounts payable
Accrued expenses
Deferred revenue
Other liabilities

Net cash used in operating activities
Cash flows from investing activities:
Capital expenditures
Proceeds from sale of fixed assets
Acquisition of GPCR Therapeutics USA Inc.
Proceeds from sale or maturity of available for sale securities
Proceeds from sale or maturity of available-for-sale securities
Proceeds from sale of subsidiary
Cash removed from the sale of KCC
Net cash used in by investing activities

Cash flows from financing activities:
Proceeds from sale of common stock
Payment of common stock financing costs
Proceeds from long-term borrowing
Payment of long-term debt fees and issuance costs
Repayment of long-term debt
Proceeds from issuance of employee stock purchase plan
Proceeds from exercise of common stock warrants
Proceeds from exercise of common stock options
Proceeds from short term debt
Payment of exercise of common stock warrants
Payments for minimum statutory tax withholding related to net share settlement of equity awards
Net cash provided by financing activities

Net (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash - beginning of year
Cash, cash equivalents, and restricted cash - end of year
Right-of-use asset acquired through operating leases
Capital expenditures (accounts payable and accrued expenses)
Debt fees (accrued expense and other noncurrent liabilities)
Common stock issuance costs (accounts payable and accrued expenses)
Cash and cash equivalents
Restricted cash included in other noncurrent assets

Comments